MC-100093 是一种具有口服活性和血脑屏障透过性的 GLT-1 表达上调剂,可上调大鼠中 GLT-1 和 xCT 的表达,减轻芬太尼诱导的 GLT-1 下调、IL-6 上调以及运动过度活跃,并能在星形胶质细胞-神经元共培养体系中上调 GLT-1 表达、增强谷氨酸摄取,同时减少乙醇的消耗量和偏好性、发挥性别特异性的类抗抑郁作用,因此可用于芬太尼过量、心境障碍以及酒精使用障碍的相关研究。
产品编号: MS-M22940 CAS No.: 1639784-02-3 分子式: C13H23N3O3 分子量: 269.34
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

MC-100093 是一种具有口服活性和血脑屏障透过性的 GLT-1 表达上调剂,可上调大鼠中 GLT-1 和 xCT 的表达,减轻芬太尼诱导的 GLT-1 下调、IL-6 上调以及运动过度活跃,并能在星形胶质细胞-神经元共培养体系中上调 GLT-1 表达、增强谷氨酸摄取,同时减少乙醇的消耗量和偏好性、发挥性别特异性的类抗抑郁作用,因此可用于芬太尼过量、心境障碍以及酒精使用障碍的相关研究。

生物实验数据

生物活性 MC-100093 is an orally active, blood-brain barrier-penetrant upregulator of GLT-1 expression that upregulates GLT-1 and xCT expression in rats, attenuates fentanyl-induced GLT-1 downregulation, IL-6 upregulation, and hyperlocomotion, upregulates GLT-1 expression and enhances glutamate uptake in astrocyte-neuron co-culture systems, and reduces ethanol consumption and preference while exerting sex-specific antidepressant-like effects, making it applicable to research on fentanyl overdose, mood disorders, and alcohol use disorder.
体外研究
(In Vitro)

MC-100093 可增强星形胶质细胞-神经元共培养体系中的谷氨酸摄取能力,其 IC50 为 0.1 μM,可使摄取量提升 23.5%。

体内研究
(In Vivo)

MC-100093 (100 mg/kg;腹腔注射;每日 1 次;连续 5 天) 可减少嗜酒大鼠的乙醇摄入量,并上调其内侧前额叶皮层 (mPFC) 和伏隔核 (NAc) 亚区中 GLT-1 与 xCT 的表达。
MC-100093 (50 mg/kg;腹腔注射;每日;第 5 至 9 天) 在芬太尼诱导雄性 BALB/c 小鼠中可逆转伏隔核 (NAc) 中 GLT-1 下调与 IL-6 上调,减轻过度自主活动,并使体内 Glycine (MS-W54471) 与 Arachidonic acid (MS-A69140) 水平恢复正常。
MC-100093 (25-100 mg/kg,腹腔注射,每日 1 次,连续 6 天) 在雌性小鼠中发挥性别特异性的类抗抑郁作用。
MC-100093 (50 mg/kg;腹腔注射;每日一次;连续 6 天) 可降低高饮酒雌性小鼠的乙醇偏好性并增加其饮水量,但对高饮酒雄性小鼠的乙醇饮酒行为无影响。

Animal Model: alcohol-preferring (P) (male/female,, 80-85 days old, chronic ethanol consumption via continuous free-choice access to 15% v/v and 30% v/v ethanol plus water for 5 weeks)
Dosage: 100 mg/kg
Administration: i.p.; once daily; 5 days
Result: Reduced ethanol consumption from Day 1-5 of treatment.
Significantly upregulated glutamate transporter 1 (GLT-1) expression in mPFC-infralimbic (IL) subregion relative to ethanol-saline and water-saline groups, reversing ethanol-induced downregulation.
Significantly upregulated cystine/glutamate antiporter (xCT) expression in mPFC-infralimbic (IL) subregion relative to ethanol-saline groups, reversing ethanol-induced downregulation.
Significantly upregulated GLT-1 expression in mPFC-prelimbic (PL) subregion relative to ethanol-saline and water-saline groups, reversing ethanol-induced downregulation.
Significantly upregulated xCT expression in mPFC-prelimbic (PL) subregion relative to ethanol-saline groups, reversing ethanol-induced downregulation.
Significantly upregulated GLT-1 expression in nucleus accumbens (NAc)-shell subregion relative to ethanol-saline and water-saline groups, reversing ethanol-induced downregulation.
Significantly upregulated xCT expression in nucleus accumbens (NAc)-shell subregion relative to ethanol-saline groups, reversing ethanol-induced downregulation.
Significantly upregulated GLT-1 expression in nucleus accumbens (NAc)-core subregion relative to ethanol-saline and water-saline groups.
Significantly upregulated xCT expression in nucleus accumbens (NAc)-core subregion relative to ethanol-saline groups, reversing ethanol-induced downregulation.
Animal Model: BALB/c (male, 7 weeks old, fentanyl overdose model)
Dosage: 50 mg/kg
Administration: i.p.; daily; days 5 to 9
Result: Attenuated fentanyl-induced hyperlocomotion, with treated mice traveling a mean total distance of 2366 cm.
Normalized fentanyl-induced reduction in glycine levels in the NAc, with no significant difference from control group glycine levels.
Prevented fentanyl-induced reduction in arachidonic acid levels in the NAc, with no significant difference from control group arachidonic acid levels.
Significantly upregulated GLT-1 protein expression in the NAc relative to fentanyl-only mice, reversing the fentanyl-induced downregulation of GLT-1.
Significantly reduced fentanyl-induced upregulation of IL-6 protein expression in the NAc, with levels not significantly different from the control group.
Did not significantly alter fentanyl-induced changes in D-glucose, D-turanose, or L-valine levels in the NAc, nor did it restore the overall fentanyl-altered NAc metabolomic profile.
Did not significantly affect Y-maze spontaneous alternation performance relative to fentanyl-only mice.
Animal Model: C57BL/6J (male and female, 8-10 weeks old)
Dosage: 25 mg/kg; 50 mg/kg; 100 mg/kg
Administration: i.p.; daily; 6 days
Result: Had no effect on body weight, distance traveled, or average velocity in the open field test in either sex at 50 mg/kg.
Had no effect on anxiety-like behaviors, including percentage of time spent in the open field center zone, center zone entries, percentage of time spent in elevated plus maze open arms, or open arm entries in either sex at 50 mg/kg.
Reduced immobility time and increased mobility time in female mice during the tail suspension test at 50 mg/kg; no changes were seen in male mice.
Reduced immobility time and increased mobility time in female mice during the forced swim test at 50 mg/kg; male mice showed increased immobility time and decreased mobility time at 50 mg/kg.
Showed a dose-dependent reduction in immobility time in female mice during the tail suspension test, with corresponding increased mobility time at higher dose.
Did not alter GLT1 protein expression relative to GAPDH in the medial prefrontal cortex or hippocampus in either sex at 50 mg/kg.
Animal Model: C57BL/6J (male and female, 8-10 weeks old, high-drinking selected via 2-bottle choice continuous access paradigm with ethanol concentration escalation from 3% to 10%)
Dosage: 50 mg/kg
Administration: i.p.; daily; 6 days
Result: Did not change ethanol intake or total liquid intake in female mice, but reduced ethanol preference and increased water intake at 50 mg/kg.
Had no effect on ethanol intake, ethanol preference, water intake, or total liquid intake in male mice at 50 mg/kg.

化学信息

分子量 269.34
分子式 C13H23N3O3
CAS No. 1639784-02-3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础